GLP-1 microdosing: definition, evidence and how people do it

There is no clinical definition. In practice, microdosing covers three different things that get lumped together. The first is starting below the labeled starting dose, for example semaglutide at 0.1 mg instead of 0.25 mg, to ease into the drug. The second is holding at a low step indefinitely instead of climbing, such as staying at tirzepatide 2.5 mg. The third is dropping to a fraction of the maintenance dose after reaching a goal weight, which is the version most people mean when they say maintenance microdosing.

The numbers people describe cluster into two ranges. For semaglutide, 0.05 to 0.5 mg weekly; the top of that range is the second label step, so a lot of microdosing is simply the early titration held in place. For tirzepatide, 0.5 to 2.5 mg weekly, where 2.5 mg is the label's tolerance step and anything below it is off the label entirely. Some descriptions use a percentage instead, 25 to 50 percent of whatever maintenance dose the person had reached.

Microdosing is only possible with vials. Wegovy and Zepbound pens deliver fixed doses, so people who microdose are using compounded multi-dose vials or grey-market powder and drawing small volumes on an insulin syringe. That dependency on vials is why the compounding changes in 2026 matter to this practice specifically. The semaglutide dosage chart and tirzepatide dosage chart show the labeled schedules these doses sit below.

No randomized trial has tested doses below the labeled range for weight loss or weight maintenance. The STEP and SURMOUNT programs tested the labeled steps and above; their lowest arms, semaglutide 0.25 mg and tirzepatide 2.5 mg, were titration steps that participants passed through in 4 weeks, not maintenance arms. There is no trial arm that held people at 0.1 mg of semaglutide or 1 mg of tirzepatide for a year and measured what happened.

The Lancet commentary in early 2025 made this point directly: microdosing is being promoted by clinics and on social media without evidence that it works for obesity. The commentary did not say it cannot work; it said nobody has shown that it does, and that selling it as a proven approach is unsupported. That is still the state of the literature in October 2026.

What does exist points the other way for the maintenance use case. The STEP 1 extension and the SURMOUNT-4 withdrawal study both found that stopping the drug led to substantial regain within a year. Those studies went from full dose to zero, not from full dose to a fraction, so they do not rule out a low dose holding weight. They do show that the pharmacology is dose-dependent and that removing it removes the effect, which is a reason to expect a reduced dose to produce a reduced effect rather than a free lunch.

Side effects are the first reason. Nausea, reflux, constipation and fatigue track the dose, and the compound pages for both drugs describe GI effects as the main reason people quit. Someone who gets adequate appetite control at semaglutide 0.5 mg and feels sick at 1 mg has a real incentive to stop climbing. That is arguably not microdosing at all; the labels for both drugs increase only as tolerated, and holding at a low step is within them.

Cost is the second. Branded pens cost the same regardless of the dose, but a compounded or grey-market vial is priced by the mg, and a 10 mg tirzepatide vial lasts four times as long at 1 mg a week as at 4 mg. For people paying out of pocket, cutting the dose by half is cutting the bill by half. The economics push toward the lowest dose that seems to work, with no clinician in the loop to say whether it is actually working.

Maintenance is the third and the one with the most hope attached. The idea is that once the weight is off, a smaller signal is enough to keep appetite in check and avoid the regain seen in the withdrawal studies. It is a reasonable hypothesis. It is also exactly what SURMOUNT-MAINTENANCE is designed to test, and until it reports, the hypothesis is untested.

Forum and clinic descriptions vary widely, and none of them are validated. For semaglutide, the most common pattern is a maintenance hold at 0.25 to 0.5 mg weekly, the first two label steps, after a period at 1 to 2.4 mg. A smaller group describes doses below 0.25 mg, such as 0.1 or 0.125 mg, measured as 4 or 5 units at 2.5 mg/mL. For tirzepatide, the common hold is 2.5 mg weekly, the tolerance step, with some people describing 1 to 1.25 mg.

The calculator handles the small volumes involved, which is where errors happen. At 5 mg/mL, 0.125 mg of semaglutide is 2.5 units, below the resolution of most syringes. People microdosing from concentrated vials often dilute further to get a measurable draw, which adds a second calculation and a second chance to get it wrong. The insulin syringe units chart covers syringe resolution.

SURMOUNT-MAINTENANCE is a Lilly trial testing whether people who have lost weight on tirzepatide can hold it on a reduced maintenance dose. It follows the SURMOUNT-4 result, where switching to placebo after 36 weeks of tirzepatide led to most of the loss returning within a year. The question it asks is the one microdosing assumes an answer to: is there a dose between full and zero that preserves the result?

Results are expected in late 2026. If reduced doses hold weight, maintenance microdosing gets a trial behind it for tirzepatide specifically, at whatever dose the trial used, which may or may not match the numbers people are using now. If reduced doses do not hold weight, the practice loses its main justification. Either way, the answer will apply to tirzepatide at the tested dose and not automatically to semaglutide or to doses below the trial's lowest arm.

Until then, the compound page's framing stands: the right dose is the lowest step that keeps appetite controlled with tolerable side effects, with the labeled steps as the floor. Our semaglutide vs tirzepatide comparison covers why the two drugs may behave differently at low doses.

Microdosing depends on vials, and vials depend on compounding. On April 30, 2026 the FDA proposed removing semaglutide, tirzepatide and liraglutide from the 503B bulks list, with the notice published in the Federal Register on May 1. The comment period closed June 29, 2026. As of October 2026 no final decision has been reported. If the proposal is finalized, outsourcing facilities could no longer compound these drugs from bulk powder outside a declared shortage.

The practical risk is that microdosing moves further from supervision. People who were getting a pharmacy vial with a labeled concentration and a prescribed volume would be reconstituting powder themselves and calculating their own draws. The buying guide tracks the regulatory status, and how to read a COA covers what testing can and cannot tell you about a vial.

The obvious risk is that it does not work and the weight returns, which is what the withdrawal data predict for a dose of zero and what nobody has measured for a dose in between. The less obvious risk is that it works partially, appetite creeps back, and the person increases the dose on their own, skipping the 4-week steps that keep GI side effects manageable. The compound pages for both drugs describe fast escalation as the number one cause of the nausea and vomiting that lead people to quit.

Finally, changing the dose changes the monitoring. Someone on a labeled dose through a clinic has a prescriber watching for pancreatitis, gallbladder disease, thyroid symptoms and, for diabetics, hypoglycemia. Someone microdosing from a vial usually does not. The GLP-1 side effects article lists the red flags that need a clinician at any dose, and are peptides safe covers the broader question.